- Conditions
- Pseudobulbar Affect (PBA)
- Interventions
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Agitation in Participants With Dementia of the Alzheimer's Type
- Interventions
- AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
- Conditions
- Dyskinesia, Parkinson's Disease
- Interventions
- AVP-923-45, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Portland, Oregon
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 111
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Healthy
- Interventions
- AVP-923, AVP-786, Itraconazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Schizophrenia
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 61
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
- Conditions
- Episodic Migraine
- Interventions
- Dextromethorphan and quinidine, Placebo
- Drug
- Lead sponsor
- Cady, Roger, M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Nuedexta, Matching Placebo
- Drug
- Lead sponsor
- Center for Neurologic Study, La Jolla, California,
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more
- Conditions
- Schizophrenia
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Cerritos, California • Garden Grove, California • National City, California + 14 more
- Conditions
- Huntington Disease, Irritability
- Interventions
- Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteer
- Interventions
- NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 223 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Lincoln, Nebraska
- Conditions
- Disinhibition Syndrome
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Intermittent Explosive Disorder
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Neurobehavioral Disinhibition
- Interventions
- Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 54
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 171
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Arrhythmia
- Interventions
- quinidine, no therapy
- Drug
- Lead sponsor
- International Registry of Asymptomatic Brugada Syndrome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 93
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Central Neuropathic Pain, Multiple Sclerosis
- Interventions
- AVP-923-45, AVP-923-30, AVP-923-20, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
- Conditions
- Pain, Diabetic Neuropathy
- Interventions
- Neurodex
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 44
- States / cities
- Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
- Conditions
- Agitation, Alzheimer's Disease
- Interventions
- AVP-923-20, Placebo, AVP-923-30
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
- Conditions
- Autism
- Interventions
- Nuedexta, Placebo
- Drug · Other
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more